Compare Innovative Industrial Properties Inc (IIPR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Inovio Pharmaceuticals Inc — how do they compare? Innovative Industrial Properties Inc trades at $61.62 (market cap $1.87B), while Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M). The key difference: Innovative Industrial Properties Inc is far larger — about 20.9× Inovio Pharmaceuticals Inc's market cap, and Innovative Industrial Properties Inc pays a 11.81% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| IIPR | INO | |
|---|---|---|
Market Cap | $1.87B | $89.27M |
Sector | Real Estate | Health |
52-Week High | $64.67 | $2.87 |
52-Week Low | $44.58 | $1.05 |
Enterprise Value | $2.25B | $60.28M |
Dividend Yield | 11.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $64.35, down slightly today, amid a bullish technical trend with strong moving average support. The REIT reported mixed quarterly earnings, with a significant beat in Q4 2025 but a miss in Q1 2026, while maintaining a high dividend yield. Recent news highlights successful debt management and cannabis rescheduling progress as positive catalysts.
Outlook is cautiously optimistic given the strong balance sheet and regulatory tailwinds, but risks include revenue volatility and high dividend payout. Analyst sentiment is mixed with a slight Hold bias, reflecting concerns over near-term earnings consistency versus long-term growth potential in the cannabis real estate sector.
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
